Related Experiment Video
Updated: Apr 16, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
84.8K
Regulatory, legislative, and policy updates with anticoagulant use
John Fanikos1, Leo F Buckley, Ahmed Aldemerdash
1Department of Pharmacy Services, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA, jfanikos@partners.org.
Journal of Thrombosis and Thrombolysis
|March 10, 2015
Summary
Millions suffer from thromboembolism yearly. This review covers recent oral anticoagulation therapy updates, focusing on improved patient outcomes, safety, and cost reduction in thrombosis management.
Area of Science:
- Cardiology
- Pharmacology
- Health Policy
Background:
- Thromboembolism is a major health issue in the US, incurring substantial costs.
- Advances in oral anticoagulation offer new therapeutic options.
- Regulatory bodies are actively involved in optimizing patient safety and outcomes.
Purpose of the Study:
- To review recent developments in anticoagulant therapy management.
- To inform clinicians about updates relevant to thrombosis prevention and treatment.
- To highlight regulatory, legislative, and policy changes impacting anticoagulation.
Main Methods:
- Review of recent literature and regulatory updates.
- Synthesis of information on oral anticoagulation therapies.
- Analysis of trends in surveillance, litigation, and oversight.
Main Results:
- Emergence of novel oral anticoagulants (NOACs) and updated guidelines.
- Increased regulatory scrutiny and policy interventions.
- Focus on balancing efficacy, safety, and cost-effectiveness.
Conclusions:
- Clinicians must stay informed about evolving anticoagulant therapies and regulations.
- Effective management of anticoagulation is crucial for preventing and treating thrombosis.
- Policy changes aim to enhance patient safety and reduce healthcare costs.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
473
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
473
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.9K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:30Venous Thrombosis IV: Nursing Management
398
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
398
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
01:25Drug Regulation
3.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.3K